Conference item
Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
- Abstract:
- Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise that our rSIV.F/HN lentiviral lung gene delivery platform, currently undergoing preclinical evaluation for cystic fibrosis gene therapy, could be used to establish protein factories within patients' lungs.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 28.8KB)
-
- Publisher copy:
- 10.1089/hum.2016.29027.abstracts
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
- Publisher:
- Mary Ann Liebert Inc Publisher's website
- Journal:
- 13th Annual Meeting of the British Society for Gene and Cell Therapy (BSGCT 2016) Journal website
- Host title:
- 13th Annual Meeting of the British Society for Gene and Cell Therapy (BSGCT 2016)
- Publication date:
- 2016-06-01
- DOI:
- ISSN:
-
1043-0342
- Source identifiers:
-
720845
Item Description
- Pubs id:
-
pubs:720845
- UUID:
-
uuid:66a643d1-7c76-4447-a7b5-8311b6e93d03
- Local pid:
- pubs:720845
- Deposit date:
- 2017-09-08
Terms of use
- Copyright holder:
- Mary Ann Liebert, Inc
- Copyright date:
- 2016
- Notes:
- © Mary Ann Liebert, Inc.
If you are the owner of this record, you can report an update to it here: Report update to this record